{"id":"NCT00660504","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","briefTitle":"Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer","officialTitle":"Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2012-02","completion":"2012-08","firstPosted":"2008-04-17","resultsPosted":"2014-07-04","lastUpdate":"2014-07-18"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer"],"interventions":[{"type":"DRUG","name":"Amrubicin Hydrochloride","otherNames":[]},{"type":"DRUG","name":"Etoposide-Cisplatin combined chemotherapy","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"1.5 years after last subject enrolled","effectByArm":[{"arm":"Amrubicin Combined With Cisplatin Group","deltaMin":11.79,"sd":null},{"arm":"Etoposide Combined With Cisplatin Group","deltaMin":10.28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":["27061082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":149},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Nausea","vomit","Decreased appetite"]}}